Patent ID: 7572772
Filing Date: 2009-08-11
Classification: A61K,C07K,Y10S

Abstract:
1. A soluble CTLA4 mutant molecule wherein the soluble CTLA4 mutant molecule is HS2, and wherein the HS2 mutant comprises: a. a portion of the extracellular region of CD28; b. a portion of the extracellular region of CTLA4 which binds B7-1 and/or B7-2; and c. the hinge, CH2 and CH3 regions of a human immunoglobulin, said portion of (a) joined to said portion of (b), said regions of (c) being joined to said portion of (a) or (b) but not both and, wherein i. said portion of (a) has an amino acid sequence beginning with lysine at position 41 and ending with isoleucine at position 114 of CD28 (SEQ ID NO:21); ii. said portion of (b) has a first amino acid sequence beginning with methionine at position 38 and ending with cysteine at position 58 of CTLA4 (SEQ ID NO: 17) and a second amino acid sequence beginning with glutamic acid at position 132 and ending with aspartic acid at position 159 of CTLA4 (SEQ ID NO: 17); and iii. said portion of (a) is located between said first and second amino acid sequences of CTLA4.